Moderna Inc. (MRNA) |
|
160.07 -7.45 (-4.45%)
|
01-21 18:30 |
|
Open: |
166.23 |
Pre. Close: |
167.52 |
|
High:
|
171.2543 |
Low:
|
157.29 |
|
Volume:
|
11,679,187 |
Market Cap:
|
64,900M |
|
|
|
|
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
172.368 - 174.022 |
174.022 - 175.023 |
|
Low:
|
153.966 - 156.011 |
156.011 - 157.248 |
|
Close:
|
157.712 - 161.06 |
161.06 - 163.084 |
|
Technical analysis |
as of: 2022-01-21 4:28:34 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 302.10  One year: 375.28 |
| Support: |
Support1: 157.29 Support2: 130.87 |
| Resistance: |
Resistance1: 258.65 Resistance2: 321.30 |
| Pivot: |
209.89 |
| Moving Average: |
MA(5): 178.60 MA(20): 219.31
MA(100): 307.41 MA(250): 253.69  |
| MACD: |
MACD(12,26): -25.33 Signal(9): -19.95 |
| Stochastic oscillator: |
%K(14,3): 1.63 %D(3): 2.10 |
| RSI: |
RSI(14): 24.62 |
| 52-week: |
High: 497.49 Low: 117.34 Change(%): 2.8 |
| Average Vol(K): |
3-Month: 12004 10-Days: 9737 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.MRNA has closed above bottom band by 2.2%. Bollinger Bands are 3.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 21 Jan 2022
U.S. studies highlight the need for COVID boosters to fight Omicron - Nasdaq
Fri, 21 Jan 2022
Moderna's stock has tumbled enough for a long-time bear to say stop selling - MarketWatch
Wed, 19 Jan 2022
Early Omicron Breakthroughs Show mRNA Vaccines' Weakness - Bloomberg
Tue, 18 Jan 2022
Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today - Nasdaq
Mon, 10 Jan 2022
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update - Yahoo Finance
Mon, 10 Jan 2022
Moderna, Inc. (MRNA) CEO Stephane Bancel on JPMorgan 40th Annual Healthcare Conference (Transcript) - Seeking Alpha
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Outperform |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
405 |
| Shares Float (M) |
367 |
|
% Held by Insiders
|
9.49 |
|
% Held by Institutions
|
61.16 |
|
Shares Short (K)
|
16,690 |
|
Shares Short P. Month (K)
|
15,290 |
Stock Financials |
|
EPS
|
16.690 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
25.000 |
|
Profit Margin
|
59.68 |
|
Operating Margin
|
64.33 |
|
Return on Assets (ttm)
|
37.2 |
|
Return on Equity (ttm)
|
109.6 |
|
Qtrly Rev. Growth
|
3065.0 |
|
Gross Profit (p.s.)
|
-1.418 |
|
Sales Per Share
|
29.177 |
|
EBITDA (p.s.)
|
19.164 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
11,570 |
|
Levered Free Cash Flow (M)
|
8,940 |
Stock Valuations |
|
PE Ratio
|
9.59 |
|
PEG Ratio
|
|
|
Price to Book value
|
6.40 |
|
Price to Sales
|
5.49 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
